A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Evobrutinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors EMD Serono Research & Development Institute
- 31 Aug 2018 Biomarkers information updated
- 16 May 2018 Planned End Date changed from 21 Apr 2021 to 5 Jul 2020.
- 16 May 2018 Planned primary completion date changed from 20 Feb 2019 to 10 Jun 2019.